Stocks and Investing Stocks and Investing
Fri, September 6, 2024

Charles Duncan Reiterated (AXSM) at Buy and Held Target at $107 on, Sep 6th, 2024


Published on 2024-10-28 14:07:04 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Buy and Held Target at $107 on, Sep 6th, 2024.

Charles has made no other calls on AXSM in the last 4 months.



There are 9 other peers that have a rating on AXSM. Out of the 9 peers that are also analyzing AXSM, 0 agree with Charles's Rating of Hold.



These are the ratings of the 9 analyists that currently disagree with Charles


  • Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $130 on, Thursday, September 5th, 2024
  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $180 on, Thursday, September 5th, 2024
  • Cerena Chen of "Wells Fargo" Initiated at Buy and Held Target at $140 on, Tuesday, September 3rd, 2024
  • Ashwani Verma of "UBS" Maintained at Strong Buy with Decreased Target to $105 on, Tuesday, August 6th, 2024
  • Jason Gerberry of "B of A Securities" Upgraded from Hold to Strong Buy and Increased Target to $106 on, Tuesday, August 6th, 2024
  • Leonid Timashev of "RBC Capital" Maintained at Buy with Decreased Target to $130 on, Tuesday, August 6th, 2024
  • Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $106 on, Wednesday, June 12th, 2024
  • Joel Beatty of "Baird" Maintained at Buy with Increased Target to $112 on, Tuesday, May 7th, 2024
  • David Hoang of "Citigroup" Maintained at Strong Buy with Decreased Target to $125 on, Tuesday, May 7th, 2024
Contributing Sources